Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Weekly Report Card

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Jun 07, 2021 11:17am

132 Views

Post# 33340070

RE:RE:RE:RE:RE:RE:Weekly Report Card

Well, there is a good chance your pessimism will prove to be incorrect. Right now, the company does have no traction with investors but LSA is something new they are trying and LSA clearly has a successful operation. So, there is good reason to believe things will change with their involvement. Moreover, on 6/21 we know we are going to get an update about cancer. If the company shares good news about cancer and the market does not react to that, particulalrly with LSA helping spread that news to investors who may not be very familiar with TH, then you can be pessimistic. But that is unlikely to be the outcome.